MarketBeat estimates November 11 results for Orgenesis stock

Published on 10/16/2026 at 01:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orgenesis stock faces an estimated November 11, 2026 results date. The company was incorporated in 2008 and runs the POCare platform.

Upcoming reporting date and company profile

MarketBeat estimated November 11, 2026 as Orgenesis' next results date.
Orgenesis was incorporated in 2008 and operates a POCare cell and gene therapy platform.
The last quoted home-market price was USD 0.06 on October 8, 2026.

ORGS, US68619K3032, Illustration mit AI erstellt.

Orgenesis (ISIN US68619K3032) faces an estimated November 11, 2026 reporting date, while its last quoted home-market price was USD 0.06 on October 8, 2026. MarketBeat also listed consensus estimates of negative USD 2.60 in earnings per share and USD 2.80 million in revenue for the expected report.

What does November 11 mean?

The date gives investors a concrete checkpoint for the company's next financial update, although MarketBeat described it as an estimate rather than a company-confirmed appointment. The same page labels the figures as consensus estimates, so they are expectations rather than reported results.

Three dates shape the record

On January 26, 2026, the company appeared in a listed 8-K filing record. On June 2, 2026, another 8-K appeared in the filing history. The chronology then moved to October 6, 2026, when MarketBeat carried a report that Orgenesis stock fell 5.20 percent.

How the platform fits

Orgenesis describes its POCare platform as a way to support localized processing and production of personalized cell and gene therapies. Its investor-relations site says the model combines therapies, technologies and a network of research institutes and hospitals. The company was incorporated in 2008 and is headquartered in Germantown, Maryland, according to a company profile from Finranks.

Price context stays historical

The last quoted home-market price stood at USD 0.06 on October 8, 2026, with the quotation identified as Nasdaq OTC. The November reporting estimate and the October price date are separate reference points, so neither establishes a current trading move for October 16, 2026.